WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing

WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing. Proceeds from this funding round will be used to advance Decibel’s clinical and preclinical product candidates, as well as to build out the company’s comprehensive hearing drug discovery and development platform and capabilities.

The WilmerHale team representing Decibel was comprised of Lia Der Marderosian, Stephanie Singer and Jared Brenner.

Read Decibel’s press release about the financing.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel